These contracts are in addition to the December 1, 2006 announcement for the award of over $230 million for Crucell’s Quinvaxem and Hepavax-Gene vaccines, and the new contracts communicated on May 13, 2008 of $130 million for supplies of Quinvaxem in 2008 and 2009.
Ronald Brus, CEO of Crucell, said: “We are very excited to have received additional Quinvaxem contracts bringing the total value of the contracts awarded to date to $0.5 billion. These awards further confirm the superior quality of our pentavalent vaccine and the continued growth we expect from Quinvaxem.”